Reports Q3 revenue $82.13M, consensus $80.25M. “The acquisition of scPharmaceuticals marks a significant expansion of our commercial capabilities and is expected to accelerate growth of our product revenues and build upon our commitment to delivering innovative, patient-centric therapies,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind (MNKD) Corporation. “With the FDA’s acceptance for review of the Afrezza pediatric sBLA, the submission of the FUROSCIX ReadyFlow Autoinjector sNDA, and continued progress in the pipeline programs, we are executing across a diversified portfolio with significant growth opportunities ahead.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNKD:
- MNKD Earnings this Week: How Will it Perform?
- Strong Revenue Growth and Strategic Developments Support MannKind’s Buy Rating
- MannKind’s Afrezza: Promising Expansion and Growth Potential with FDA sBLA Acceptance
- MannKind announces U.S. FDA accepted sBLA for Afrezza Inhalation Powder
- MannKind Completes Acquisition of scPharma